LUCENTIS solution for intravitreal injection 10mg/mL [retinopathy of prematurity] (ルセンティス硝子体内注射液10mg/mL［未熟児網膜症］)

Država: Japan

Jezik: engleski

Izvor: すりの適正使用協議会 RAD-AR Council, Japan

Aktivni sastojci:

Ranibizumab(genetical recombination)

Dostupno od:

Novartis Pharma K.K.

INN (International ime):

Ranibizumab(genetical recombination)

Farmaceutski oblik:

injection

Uputa o lijeku

Drug Information Sheet("Kusuri-no-Shiori")
Injection
Revised: 01/2023
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
LUCENTIS SOLUTION FOR INTRAVITREAL INJECTION
10MG/ML [RETINOPATHY OF PREMATURITY]
ACTIVE INGREDIENT:
Ranibizumab(genetical recombination)
DOSAGE FORM:
injection
IMPRINT OR PRINT ON WRAPPING:
EFFECTS OF THIS MEDICINE
This medicine inhibits vascular endothelial growth factor (VEGF) which
is involved in formation
and growth of retinal vessels, suppresses the growth of abnormal new
blood vessels, and
suppresses the progression of retinopathy of prematurity.
It is usually used to treat retinopathy of prematurity.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
If you have: ocular/periocular infections or suspected of them,
inflammation within the eye, a
history of stroke or transient ischemic attack.
・If you are taking any other medicinal products. (Some medicines may
interact to enhance or
diminish medicinal effects. Beware of over-the-counter medicines and
dietary supplements
as well as other prescription medicines.)
DOSING SCHEDULE (HOW TO TAKE THIS MEDICINE)
・
Your dosing schedule prescribed by your doctor is((         

to be written by a healthcare
professional
))
・In general, administer by intraocular (intravitreal) injection
once. After at least 1 month
treatment interval, additional treatment may be given as needed.
PRECAUTIONS WHILE TAKING THIS MEDICINE
POSSIBLE ADVERSE REACTIONS TO THIS MEDICINE
The most commonly reported adve